Merck (NYSE: MRK) spinoff Organon (NYSE:OGN) today announced the completion of its acquisition of Alydia Health for up to $240 million.
Alydia Health develops treatments centered around preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding. The company designed its Jada system to control and treat abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.
Jersey City, N.J.-based Organon announced an agreement for the acquisition in March. Total consideration amounts to $240 million, including a $215 million cash payment, of which Merck paid $50 million upon signing. Organon paid the remaining $165 million at closing and the final $25 million will potentially arrive as a contingent milestone payment.
“Organon’s acquisition of Alydia Health expands our portfolio into the medical device category and underscores our commitment to identify options for women’…